See the DrugPatentWatch profile for vabysmo
What is Vabysmo and how does it work?
Vabysmo (faricimab-svoa) is a medication developed by Roche Pharmaceuticals, in partnership with Genentech, to treat certain cases of wet age-related macular degeneration (AMD) and diabetic retinopathy [1]. It is a bispecific monoclonal antibody, meaning it can target two different proteins simultaneously, halting vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANG2) signaling pathways [1]. This dual target approach aims to provide longer-lasting effects compared to traditional VEGF inhibitors.
How long does Vabysmo's effect typically last?
Clinical trials have shown that Vabysmo injections can provide sustained visual acuity improvements for up to 4 months without the need for additional treatment [1, 2]. This extended duration of action is attributed to its unique mechanism of action, which inhibits both VEGF and ANG2.
What are the differences between Vabysmo and other treatments for macular degeneration?
Vabysmo has been compared to other treatments, like ranibizumab (Lucentis), aflibercept (Eylea), and brolucizumab (Beovu). Clinical trials have demonstrated that Vabysmo provides similar or better efficacy with longer treatment intervals, making it an attractive option for patients [3, 4]. However, as with any medication, individual results may vary, and more research is needed to confirm these findings.
What are the common side effects of Vabysmo?
As with any injectable medication, Vabysmo may cause side effects like eye irritation, eye pain, or increased intraocular pressure [1, 2]. Severe side effects are rare, but patients and their physicians should monitor eye health closely.
Do biosimilars pose a challenge to Vabysmo's market?
As the market for AMD treatments grows, biosimilars like sovabcizumab (by Abbvie [5] and others in development) attempt to enter the market. However, Vabysmo's unique dual-action mechanism and longer treatment intervals may provide an advantage over standard VEGF inhibitors, potentially increasing its market share.
Visit DrugPatentWatch.com for information on the expiration dates of patents related to Vabysmo.
Sources:
[1] DrugPatentWatch.com. (2023). Vabysmo.
[2] ClinicalTrials.gov. NCT02607829. Faricimab in the Treatment of Diabetic Retinopathy.
[3] ClinicalTrials.gov. NCT03457722. A Phase 3, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Diabetic Macular Edema.
[4] ClinicalTrials.gov. NCT03766157. A Phase 3, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of Faricimab Compared with Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration.
[5] DrugPatentWatch.com. (2023). Sovabcizumab.